Kell Østerlind

7.6k citations
105 papers · 5.8k · 2 hit papers · h-index 38

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Peptidase Inhibition and Analysis
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Research Studies 51
    • Peptidase Inhibition and Analysis 15
    • Pancreatic and Hepatic Oncology Research 11
    • Neuroendocrine Tumor Research Advances 37

Kell Østerlind

100 papers receiving 5.6k citations

Kell Østerlind's Hit Papers

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial 2008 · 1.0k citations
1.0k0+11+22Years since publication2505007501000

Peers

Kell Østerlind
Comparison fields: 5 of 126
  • Oncology 3.3k
  • Pulmonary and Respiratory Medicine 1.9k
  • Epidemiology 1.4k
  • Cancer Research 561
  • Hepatology 127
Replace Antônio Rossi with:
Antônio Rossi Italy
Anders Mellemgaard Denmark
Peter Harper United Kingdom
F. Andrew Dorr United States
Vittorio Gebbia Italy
Gregory P. Kalemkerian United States
P Dombernowsky Denmark
Kyoichi Kaira Japan
Thierry Lecomte France
Randolph S. Marks United States
Kell Østerlind relative to Antônio Rossi Italy Antônio Rossi's profile →
Citations per field
00.5×1.5×2.3×
Antônio Rossi · 1×
Citations per year

Countries citing papers authored by Kell Østerlind

Since Specialization
Citations

This map shows the geographic impact of Kell Østerlind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kell Østerlind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kell Østerlind more than expected).

Fields of papers citing papers by Kell Østerlind

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kell Østerlind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kell Østerlind. The network helps show where Kell Østerlind may publish in the future.

Co-authors

The 25 scholars most cited alongside Kell Østerlind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kell Østerlind Line = papers co-authored together Kell Østerlind links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 105 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Hit paper breakdown →
20081012
2
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
Hit paper breakdown →
1992935
3 1972332
4
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
1994258
5 1995211
6 1989195
7 1987179
8 1976122
9 2016103
10 1986100
11 198383
12 198781
13 199677
14 201376
15 201172
16
Staging and prognostic factors in small cell carcinoma of the lung.
198372
17 198671
18 201670
19 201567
20 198566

About Kell Østerlind

Kell Østerlind is a scholar working on Oncology, Epidemiology, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 105 papers that have together received 5.8k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (51 papers), Neuroendocrine Tumor Research Advances (37 papers), Lung Cancer Treatments and Mutations (18 papers), Peptidase Inhibition and Analysis (15 papers), Cancer therapeutics and mechanisms (12 papers), Pancreatic and Hepatic Oncology Research (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Neuroblastoma Research and Treatments (5 papers). The work is most often cited by research in Oncology (3.3k citations), Pulmonary and Respiratory Medicine (1.9k citations), Epidemiology (1.4k citations), Cancer Research (561 citations) and Hepatology (127 citations). Kell Østerlind has collaborated with scholars based in Denmark, United Kingdom and United States. Frequent co-authors include Heine H. Hansen, P Dombernowsky, Jørgen Gliemann, J. Vinten, Per Kragh Andersen, Fred R. Hirsch, M Hansen, Steen Gammeltoft, Daniel C. Ihde and Merrill S. Kies. Their work appears in journals such as Lung Cancer, Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology and Acta Oncologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact